A Study to Evaluate the Bioequivalence of DA-5230 Compared to DA-5230-R

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of DA-5230 With DA-5230-R in Healthy Adult Volunteers

A study to evaluate the bioequivalence of DA-5230 compared to DA-5230-R

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of DA-5230 With DA-5230-R in Healthy Adult Volunteers

Inclusion Criteria:

• Healthy participants aged 19 to 55 years at the time of screening visit
• Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit

Exclusion Criteria:

• Participants who have received an investigational product in another clinical trial or a bioequivalence study within 6 months prior to the first dosing
• Participants deemed unsuitable for participation in this clinical trial by the investigator